Nanobac Pharmaceuticals Inc. Announces Investor Conference Call, Hosted by John Stanton, Chairman.

Dr. Benedict S. Maniscalco, Head of Research & Development, to Give Detailed Update on Nanobac Discoveries

TAMPA, Fla. -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) announces it will host an investor conference call on Thursday, November 16, 2006, to begin at 4:15 P.M. Eastern Time.

In discussing the conference call, John Stanton, Chairman of Nanobac Pharmaceuticals Inc., stated, "We are thrilled with the recent preliminary results we are obtaining at Nanobac bringing new scientific support to earlier findings that the pathophysiology of calcification in vascular and other organ systems involving calcifying nanoparticles.

"Our scientific team has been working diligently on our previously announced research initiatives. In an effort to explain our latest discoveries, Dr. Maniscalco will give a detailed description of the recently released video of decalcifying Calcifying Nanoparticles (CNPs) as well as the status of all of our research initiatives. We have a commitment to our shareholders as well as the investment community for high level disclosure and communication. We look forward to updating interested parties on recent developments."

To hear the conference call as it takes place:
Call 800-391-2548 in the United States or;
Call 866-627-1646 in Canada or;
Call 302-709-8328 Internationally

Verbal Passcode: VT18107

To hear a recording of the call (available for 30 days
following the conference call):
Call 800-355-2355 in the United States;
Call 402-220-2946 in Canada or Internationally
Pin Code: 18107

About Nanobac Pharmaceuticals:

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies, and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.

Multimedia Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5265147

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.